Arcutis Biotherapeutics, Inc. (ARQT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Todd Franklin Watanabe M.A. | President, CEO & Director | 1.01M | -- | 1968 |
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder & Independent Director | 60.83k | -- | 1955 |
| Dr. Patrick E. Burnett M.D., Ph.D. | Senior VP & Chief Medical Officer | 722.94k | -- | 1972 |
| Mr. L. Todd Edwards | Senior VP & Chief Commercial Officer | 755.64k | -- | 1964 |
| Mr. David J. Topper | Senior VP & Chief Financial Officer | -- | -- | 1958 |
| Mr. Rajvir Madan | Chief Digital & Technology Officer | -- | -- | -- |
| Ms. Latha Vairavan | Vice President of Finance & Investor Relations | -- | -- | -- |
| Ms. Courtney Barton | VP and Chief Compliance Officer & Privacy Officer | -- | -- | 1983 |
| Mr. Masaru Matsuda Esq., J.D. | Senior VP, General Counsel & Corporate Secretary | 626.22k | -- | 1971 |
| Ms. Amanda Sheldon | Head of Corporate Communications | -- | -- | -- |
Arcutis Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 296
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Corporate Governance
Upcoming Events
August 6, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC
Arcutis Biotherapeutics, Inc. Earnings Date